At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
Placebo +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Placebo and Risankizumab for Dermatitis. Completed, enrolled 172 participants across 65 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis
CountriesAustralia, Canada, Japan, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionOct 2020
Study CompletionApr 2021
TodayJul 2026
First PostedOct 15, 2018
Enrollment StartDec 27, 2018
Primary CompletionOct 28, 2020
Study CompletionApr 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.7 years ago
Interventions
Placebobiological
subcutaneous (SC) injection
Risankizumabbiological
subcutaneous (SC) injection